|
Last Updated: Apr 16, 2008 - 5:52:06 PM |
Exubera (insulin human rDNA origin) Inhalation Powder
-
Audience: Endocrinologists, pulmonologists, pharmacists, patients
[Posted 04/09/2008] Pfizer informed healthcare professionals and
patients of updated safety information in the WARNINGS section of
prescribing information for Exubera, a short-acting insulin you breathe
in through your mouth using the Exubera inhaler that helps to control
high blood sugar in adults with diabetes.
There have been 6 newly
diagnosed cases of primary lung malignancies in clinical trials among
Exubera-treated patients, and 1 newly diagnosed case among comparator
treated patients. There has also been 1 post-marketing report of a
primary lung malignancy in an Exubera-treated patient. There were too
few cases to determine whether the emergence of these events is related
to Exubera. All patients who were diagnosed with lung cancer had a
prior history of cigarette smoking. Because of limited availability of
Exubera, healthcare professionals should seek alternative treatment
options to maintain patients' glycemic control.
[April 9, 2008 - Dear Healthcare Professional Letter - Pfizer, Inc.]
[April 9, 2008 - Dear Patient Letter - Pfizer, Inc.]
© 2004-2008 by foodconsumer.org unless otherwise specified
Top of Page
